Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring.

@article{Mcdonald2004ReportFT,
  title={Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring.},
  author={Donald M. Mcdonald and Beverly A. Teicher and William G. Stetler-Stevenson and Sylvia S. W. Ng and William Douglas Figg and Judah Folkman and Douglas Hanahan and Robert Auerbach and Michael S O'reilly and Roy S Herbst and David A. Cheresh and Michael S Gordon and Alexander M. M. Eggermont and Steven K. Libutti},
  journal={Journal of immunotherapy},
  year={2004},
  volume={27 2},
  pages={
          161-75
        }
}
The field of tumor angiogenesis has seen explosive growth over the last 5 years. Preclinical as well as early clinical evaluation of novel compounds is progressing at a rapid pace. To gain a perspective on the field and to take stock of advances in the understanding of molecular mechanisms underlying the process of tumor angiogenesis as well as ways of monitoring the activity of agents, the Society for Biologic Therapy and the National Cancer Institute's Vascular Biology Faculty convened a… Expand
Biomarker and Therapeutic Studies of Antibodies and Small Molecules that Target EGFR
The field of targeted cancer therapy has progressed in recent years with the approval of new oncology drugs. Coupled with the benefits that these agents provide, has come an appreciation forExpand
Imaging hypoxia and angiogenesis in tumors.
There is a clear need in cancer treatment for a noninvasive imaging assay that evaluates the oxygenation status and heterogeneity of hypoxia and angiogenesis in individual patients. Such an assayExpand
SURROGATE MARKERS PREDICT ANGIOGENIC POTENTIAL AND SURVIVAL IN PATIENTS WITH GLIOBLASTOMA MULTIFORME
TLDR
These studies suggest that plasma and circulating CD133+ vascular endothelial growth factor receptor 2+ proangiogenic cells are present in the peripheral blood of patients with glioma and can be used as a surrogate biomarker to measure tumor angiogenicity. Expand
Dose-Dependent Increases in Circulating TGF-α and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent
TLDR
Treatment-induced increases in circulating ligands, particularly TGF-α, should be serially assessed in clinical trials of anti-EGFR therapeutic antibodies as potential biomarkers to aid in determination of the optimal biological dose. Expand
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis.
TLDR
A striking correlation between highly genetically heterogeneous bFGF- or VEGF-induced angiogenesis and intrinsic CEC or CEP levels measured by flow cytometry is shown, among eight different inbred mouse strains. Expand
VEGI-192, a New Isoform of TNFSF15, Specifically Eliminates Tumor Vascular Endothelial Cells and Suppresses Tumor Growth
TLDR
The findings indicate that VEGI is an endogenous inhibitor of angiogenesis, and that systemic administration of the V EGI-192 isoform resulted in inhibition of tumor angiogenic and growth. Expand
Angiogenesis in gliomas.
TLDR
This chapter focuses on the molecular mechanism of glioma angiogenesis and summarizes some of the therapeutic approaches based on antiangiogenesis. Expand
The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen‐independent prostate cancer
  • W. Figg
  • Medicine
  • Clinical pharmacology and therapeutics
  • 2006
TLDR
The first antiangiogenic agent (bevacizumab Avastin; Genentech, Inc, South San Francisco, Calif]), and much effort has been devoted to inhibiting angioenesis as a means of controlling tumor growth. Expand
Integrin Imaging to Evaluate Treatment Response
TLDR
The favourable in vivo kinetics and tumour targeting properties of several novel RGD containing peptides that have the ability to monitor tumour vascularity non-invasively in a variety of preclinical tumor models should enhance the mechanistic understanding of how novel therapeutic strategies impact upon tumors. Expand
Targets and Approaches for Cancer Drug Discovery
TLDR
This chapter provides an introduction to the field of cancer drug discovery, focusing on a subset of current targets and giving a brief overview of approaches for identification of leads and sources of materials for drug discovery efforts. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 75 REFERENCES
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin.
TLDR
These initial data suggest that rh-Endo has measurable effects on tumor blood flow and metabolism and induces endothelial and tumor cell apoptosis even in the absence of demonstrable anticancer effects. Expand
Angiogenesis research: guidelines for translation to clinical application.
TLDR
Clinical testing ofAngiogenesis inhibitors has accentuated the need for surrogate markers of tumor angiogenesis activity, and microvessel density, so valuable as a prognostic indicator of metastatic risk, cannot determine efficacy of an angiogenic inhibitor. Expand
Angiogenesis inhibitors in lung cancer
TLDR
It is anticipated that these new targeted therapies will play an important role, along with cytotoxic and radiation therapies, in the management of metastatic disease. Expand
Angiogenesis: a target for cancer therapy.
TLDR
The signal transduction mechanisms of angiogenic molecules, the development of specific inhibitors and their translation into clinical studies and, finally, the new perspectives in antiangiogenic therapy are discussed. Expand
Molecular plasticity of human melanoma cells
TLDR
The data summarized in this review describe the molecular profile of aggressive cutaneous and uveal melanoma cells as that of multiple phenotypes similar to a pluripotent, embryonic-like stem cell, and some of the key molecular events that regulate the process of melanoma vasculogenic mimicry are described. Expand
Angiogenesis and antiangiogenic approaches to sarcomas
TLDR
The evidence supporting the use of antiangiogenic therapies for adult soft tissue sarcomas is reviewed, with promising results having already been seen. Expand
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment.
  • S. Hobbs, W. Monsky, +4 authors R. Jain
  • Medicine, Biology
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1998
TLDR
Delivery may be less efficient in cranial tumors than in subcutaneous tumors, delivery may be reduced during tumor regression induced by hormonal ablation, and permeability to a molecule is independent of pore cutoff size as long as the diameter of the molecule is much less than the pore diameter. Expand
Surrogate markers in antiangiogenesis clinical trials
TLDR
This review summarises the currently available clinical data on the development of surrogate markers of angiogenesis inhibitors and indicates that new methods and surrogate markers to assess these agents' biological activity are crucial for their successful development. Expand
Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic.
TLDR
Many cancers are intrinsically resistant to chemotherapy and most of the remainder, which are initially responsive, usually acquire resistance afterwards, so the hypothetical beneficial anti-angiogenic side effect of chemo-therapy would seem negligible, or minimal, at best. Expand
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
TLDR
Combinatorial targeting of receptor tyrosine kinases shows promise for treating multiple stages in tumorigenesis, most notably the often-intractable late-stage solid tumor. Expand
...
1
2
3
4
5
...